Research Article
Ranolazine Improves Glycemic Variability and Endothelial Function in Patients with Diabetes and Chronic Coronary Syndromes: Results from an Experimental Study
Table 2
Glycemic variability at baseline and after three months.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
compared with 3-month results in the ranolazine cohort; values are or median(Q1, Q3). CV: coefficient of variation; FPG: fasting plasma glucose; HbA1c: haemoglobin A1c; MAGE: mean amplitude glycemic excursions; SD: standard deviation; TAR: time above range; TBR: time below range; TIR: time in range. |